Clinical trials: Respiratory Allergy
Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)
This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days…
- Trial name
- NCT00794846
- Testing
- Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec)
- Volunteers
- 124 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease (COPD), Asthma
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
AZD7594 is a non steroidal, potent and selective modulator of the glucocorticoid receptor (GR) under development for once daily inhaled treatment of chronic obstructive pulmonary disease (COPD) and asthma.
- Trial name
- NCT02967159
- Testing
- Abediterol, AZD7594, AZD7594/abediterol
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Bronchial
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.
- Trial name
- NCT00489346
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year
- Volunteers
- 994 people
- Sponsor
- Organon and Co
Asthma
Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg
The purpose of this study is to estimate the relative potency for bronchoprotective effect of formoterol Novolizer 12 µg (test) compared to formoterol Aerolizer 12 µg (reference).
- Trial name
- NCT01256086
- Testing
- Formatris 24µg, Formatris 12µg, Foradil P 24µg
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
RV6153 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02517359
- Testing
- RV6153 single dose, RV6153 14 day repeat dose, RV6153 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)
The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol…
- Trial name
- NCT00379288
- Testing
- mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID, Fluticasone/Salmeterol 250/50 mcg BID
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Mild to Moderate Bronchial Asthma
Safety and Efficacy of SA09012 in Asthma
Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients
- Trial name
- NCT01740986
- Testing
- SA09012 Low dose, SA09012 High dose
- Where
- 14 sites in South Korea
- Volunteers
- 225 people
- Sponsor
- SamA Pharmaceutical Co., Ltd
Allergic Rhinitis
Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis
This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge model.
- Trial name
- NCT00758446
- Testing
- BLX-028914
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Dart NeuroScience, LLC
Allergic Rhinitis
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine
Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for…
- Trial name
- DESCUBRA (NCT06916884)
- Testing
- Desloratadine / Betamethasone in fixed dose, Desloratadine
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Bronchial Asthma
Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg
- Trial name
- NCT05292976
- Testing
- Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference)
- Where
- United States
- Sponsor
- Aurobindo Pharma Ltd
Asthma
Pharmacokinetics in Adolescents
The purpose of this study is to study pharmacokinetics in adolescents.
- Trial name
- PEAK (NCT01196689)
- Testing
- AZD1981 100 mg twice daily for 61/2 days
- Where
- Sweden
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Asthma, Vitamin D Deficiency
Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations.
The role of vitamin D in respiratory health remains uncertain. Whether vitamin D reduces clinically important exacerbations of childhood asthma remains uncertain.
- Trial name
- NCT01395589
- Testing
- Vitamin D
- Where
- Qatar
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Asthma
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
Rationale for the current trial is to evaluate the efficacy and safety of three doses (1.25 µg, 2.5 µg and 5.0 µg ex mouthpiece) of tiotropium inhalation solution in patients with moderate persistent asthma who are still…
- Trial name
- NCT01233284
- Testing
- tiotropium bromide 2.5µg once daily, tiotropium bromide high dose once daily, tiotropium bromide 1.25µg once daily
- Where
- 19 sites in Austria, Germany and 1 more
- Volunteers
- 149 people
- Sponsor
- Boehringer Ingelheim
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergic Rhinitis
Efficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to Pollen
Study design: Randomized, controlled, double-blind, parallel, multicentre multinational clinical trial, to show superiority of an active therapy as compared to a control therapy on intermittent or persistent Allergic Rhinitis.
- Trial name
- NCT01478425
- Testing
- Lipidic Microemulsion, Saline
- Where
- 9 sites in Spain, Sweden
- Volunteers
- 110 people
- Sponsor
- Reig Jofre Group
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172821
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 125 sites in United States, Brazil and 9 more
- Volunteers
- 1,032 people
- Sponsor
- Boehringer Ingelheim
Seasonal Allergic Rhinitis
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
The purpose of the study is to determine whether VAK694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.
- Trial name
- NCT01018693
- Testing
- VAK694; Alutard Avanz SQ
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Perennial
WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis
Study to investigate the efficacy of WAL801CL Dry Syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of WAL801CL Dry Syrup compared to ketotifen fumarate and to confirm…
- Trial name
- NCT02182544
- Testing
- WAL801CL dry syrup, Ketotifen fumarate dry syrup
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.